Pfizer Stock News

Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trusted regulatory process and could sow public distrust in vaccinations and federal health agencies.

U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, has been making sweeping changes to reshape U.S. regulation of vaccines, food and medicine.

Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday.

Alexandros Michailidis / iStock Editorial via Getty Images Pfizer Pharmaceutical company Pfizer Inc.

Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples, making it attractive for income-focused investors despite recent underperformance. The company faces significant patent cliffs, risking about $20 billion in annual revenue, and is unlikely to avoid revenue declines in the next few years. Management is responding with cost cuts, acquisitions, and licensing deals, but...

Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.

Pfizer Inc. (NYSE:PFE ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ET Company Participants Albert Bourla - Chairman of the Board & CEO Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider Great. Good morning, everyone, and welcome to our 46th Annual Global Healthcare Conference.